检索结果-南通市图书馆

Journal of Environmental Science and Engineering(A) 2015年第2期4卷 104-106页

作者： mbayo lukasu Kalumba Kambote Kasamba Ilunga Ntambue Mukengeshayi Kabongo Katabwa Center of Excellence in Care of HIV/AIDS (Human Immunodefieiency Virus/Acquired Immune Deficiency Syndrome) University of Lubumbashi Lubumbashi 1825 Democratic Republic of Congo Department of Laboratory University of Lubumbashi Lubumbashi 1825 Democratic Republic of Congo School of Public Health University of Lubumbashi Lubumbashi 1825 Democratic Republic of Congo

Tuberculosis is a disease of poverty. It is also a disease that prevents escaping poverty. There is a case report of disseminated tuberculosis with peritoneal involvement and peritoneal responsible for the clinical manifestations that may delay diagnosis. This location deserves mention as a share of expansion of tuberculosis in the presence of abdominal pain and bread signs of lung disease at a lower cost balance.

关键词： Diagnostic approach A1DS (acquired immune deficiency syndrome) peritoneal tuberculosis.

Evolution of the Immune Status in Children Infected with HIV/AIDS on Antiretroviral Treatment in Lubumbashi, Democratic Republic of Congo

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Environmental Science and Engineering(A) 2014年第4期3卷 219-223页

作者： mbayo lukasu Kazadi Mwadianvita Kalumba Kambote Kasamba Ilunga Kabongo Katabwa Ntambue Mukengeshayi Wembonyama Okitosholo Center of Excellence in Care of HIV/AIDS University of LubumbashL Lubumbashi 1885 Democratic Republic of Congo Department of Laboratory University of LubumbashL Lubumbashi 1885 Democratic Republic of Congo School of Public Health University of Lubumbashi Lubumbashi 1885 Democratic Republic of Congo

The objective was to describe the immunological status among children infected with HIV （human immunodeficiency virus） at baseline and their change during the treatment. This longitudinal study conducted at the Center of Excellence in Lubumbashi from 2nd semester, 2011 to the 2nd semester, 2012, examined the records of children who had been receiving antiretroviral therapy for 48 weeks. A count of CD4 ＋ T lymphocytes was performed at the beginning, 24 weeks, and 48 weeks of treatment. The immunological status was defined by the 1996 CDC （centers for disease control） immunological categories. All the children were on zidovudine, lamivudine/nevirapine or Efavirens. At initiation of treatment, severe immunosuppression was found in 56%, moderative in 28% and lacked in 16% of cases. Furthermore, after 48 weeks of treatment, a change in the immunological status was observed in 42% of cases. In contrast, 58% of cases kept in their original status. In this cohort, the immune status has not undergone significant change.

关键词： HIV infection antiretroviral therapy immunological status Lubumbashi

Determinants of the Sensorineural Hearing Loss in Patients with Multidrug-Resistant Tuberculosis in Kinshasa (Democratic Republic of the Congo): A Prospective Cohort Study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Otolaryngology and Head & Neck Surgery 2023年第6期12卷 411-425页

作者： Mireille Avilaw Mpwate Eddy Mampuya Mbambu Gabriel Mabuaka Lema Christian Nzanza Matanda Dominique Mayuku Mupepe Michel Kayomo Kaswa Murielle Luengiladio Aloni Nicole Muzutie Anshambi Fabrice Mankangu Matuta Luc Losenga lukasu Serge Katya Mpwate Pierre Zalagile Akilimali Innocent Murhula Kashongwe Zacharie Munogolo Kashongwe Jean Marie Ntumba Kayembe Richard Nzanza Matanda Department of Otorhinolaryngology University Hospital of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of The Congo Division of Cardiology Department of Internal Medicine University Hospital of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of The Congo National Tuberculosis Control Program in Democratic Republic of The Congo Kinshasa Democratic Republic of The Congo Provincial Coordination for The Fight against Tuberculosis Kinshasa Democratic Republic of The Congo Multidrug-Resistant Tuberculosis Unit “Centre d’Excellence Damien” Damien Foundation Kinshasa Democratic Republic of The Congo Department of Anatomy-Pathology University Hospital of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of The Congo Kinshasa School of Public Health Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of The Congo Pneumology Unit Department of Internal Medicine University Hospital of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of The Congo

Background: The onset of the hearing loss is a major challenge during the treatment of multidrug-resistant tuberculosis (MDR-TB). Aminoglycoside-based regimens, to a lesser extent based on bedaquiline, induce ototoxic sensorineural hearing loss. Research on risk factors is essential to enable high-risk individuals to benefit from preventive measures in settings with limited resources. Objective: This study aimed to assess the determinants of the hearing loss in patients with MDR-TB. Methods: This prospective multicenter cohort study included 337 patients with MDR-TB. It was performed in Kinshasa (Democratic Republic of the Congo) between January 2020 and January 2021. Sociodemographic, clinical, biological, therapeutic, and audiometric data were exported and analyzed using Stata 17 and MedCalc. The fixed-effect linear regression panel model was used to assess the degree of the hearing loss over time according to the following covariates: therapeutic regimen (aminoglycosides, bedaquiline, or alternate), stage of chronic kidney disease (CKD), age at inclusion, body mass index, serum albumin level, HIV status, alcohol intake, hypertension, and hemoglobin level. The Hausman test was used to select between fixed- and random-effect estimators. The threshold for statistical significance was set at p Result: A total of 236 patients (70%) received an aminoglycoside-based regimen, 61 (18%) received a bedaquiline-based regimen, and 40 (12%) received aminoglycosides relayed by bedaquiline. The frequency of the hearing loss increased from 62% to 96.3% within six months for all therapeutic regimens. The Hearing loss worsened, with moderate (72.4%) and profound (16%) deafness being predominant. An Exposure to the treatment for more than one month (β coeff: 27.695, Se: 0.793, p β coeff: 6.102, Se: 1.779, p β coeff: 5.610, Se: 1.682, p = 0.001), and an eGFR β coeff: 6.730, Se: 2.70, p = 0.013) were the independent risk factors associated with the hearing loss in patients with MDR-TB

关键词： Multidrug-Resistant Tuberculosis Determinants Hearing Loss DRC

Sensorineural Hearing Loss in Multidrug-Resistant Tuberculosis Patients in Kinshasa (Democratic Republic of Congo): Prospective Cohort Study of Therapeutic Regimen with Aminoglycoside versus Bedaquiline

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Tuberculosis Research 2023年第3期11卷 109-119页

作者： Mireille A. Mpwate Eddy M. Mbambu Christian N. Matanda Gabriel M. Lema Michel K. Kaswa Murielle L. Aloni Nicole M. Anshambi Fabrice M. Matuta Luc L. lukasu Dominique M. Mupepe Serge K. Mpwate Pierre Z. Akilimali Zacharie M. Kashongwe Richard N. Matanda Department of Otorhinolaryngology University Clinics of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of Congo National Tuberculosis Control Program in the Democratic Republic of Congo Kinshasa Democratic Republic of Congo Provincial Coordination for the Fight against Tuberculosis Kinshasa Democratic Republic of Congo Multidrug-Resistant Tuberculosis Unit “Centre d’Excellence Damien” Damien Foundation Kinshasa Democratic Republic of Congo Division of Cardiology Department of Internal Medicine University Clinics of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of Congo Department of Anatomy-Pathology University Clinics of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of Congo Kinshasa School of Public Health Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Pneumology Unit Department of Internal Medicine University Clinics of Kinshasa Kinshasa 11 University of Kinshasa Kinshasa Democratic Republic of Congo

Context: Multidrug-resistant tuberculosis (MDR-TB) remains a major public health problem in developing countries such as the Democratic Republic of Congo (DRC), which continues to face the emergence of MDR-TB cases. Because of the ototoxic effects of AGs, the World Health Organization (WHO) has recommended the introduction of the bedaquiline regimen. However, very few data are available regarding the susceptibility of bedaquiline to induce hearing loss, hence the present study set out to compare the AG-based regimen and the bedaquiline-based regimen in the occurrence of hearing loss in MDR-TB patients. Methods: This is a prospective multicenter cohort study that included 335 MDR-TB patients, performed in Kinshasa (DRC) during the period from January 2020 to January 2021. Sociodemographic, clinical, biological and audiometric data were analyzed using Stata 17. Repeated-measures analysis of variance was used to compare changes in the degree of hearing loss over time between the two groups of patients on AG and bedaquiline regimens. The double-difference method was estimated using regression with fixed-effects. A p value < 0.05 was considered the threshold for statistical significance. Results: The degree of hearing loss was similar between the two groups at the first month [AGs (28 dB) vs BDQ (30 dB);p = 0.298]. At six months, the mean degree of hearing loss was significantly greater in the aminoglycoside regimen group [AGs (60.5 dB) vs BDQ (44 dB);p < 0.001]. The double difference was significant, with a greater increase in hearing loss in the AGs group (diff-in-diff 18.3;p < 0.001). After adjustment for age and serum albumin, the group receiving the AG-based regimen had a 2-point greater worsening than those with bedaquiline at the sixth month (diff-in-diff 19.8;p Conclusion: Hearing loss is frequent with both treatment regimens, but more marked with the Aminoglycoside-based regimen. Thus, bedaquiline should also benefit for audiometric monitoring in future MDR-TB p

关键词： Multidrug-Resistant Tuberculosis Aminoglycosides Bedaquiline Hearing Loss